SYSMEX CORPORATION
March 5, 2015
Sysmex Corporation
Announcement of Organizational and Personnel Changes
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today its decision to implement organizational and personnel changes, effective April 1, 2015, as detailed below.
These organizational changes are intended to enhance the level of management and
accelerate strategic implementation by augmenting functionality across businesses to achieve greater Group synergies. In addition, these changes put in place a structure to further promote business in non-hematology fields1.
1． Organizational Changes
(1) Enhancing the Level of Management
a) Strengthening the Business Planning Function to Enhance Group Management
・ We will establish the Corporate Business Planning Division as a dedicated organization. In addition to creating management strategy and business
plans, the division will be tasked with providing support to enable agile decision-making by top management in light of increasingly sophisticated businesses and technologies.
b) Augmenting the Corporate Communications Function to Meet the Needs of
Diverse Stakeholders
・ We will newly establish the Corporate Communication Division. In addition to conducting brand promotion activities to augment corporate value and spread
awareness of the Company's future prospects, the division will conduct CSR and environmental activities with the aim of fostering bilateral communications to enhance Sysmex's prestige and bolstering overall management quality.
(2) Accelerating Strategic Implementation
a) Augmenting Functionality across Businesses to Achieve Greater Group
Synergies
・ We will newly establish the Solution Development Division to consolidate functions related to product development and manufacturing across fields;
promote product development employing network solutions, laboratory automation and FCM2 technology; and support efforts to build value in each business unit.
・ In line with the Group's increasing scale, we will establish the Manufacturing
Management Division to consolidate functions related to production planning and production technology in the aim of increasing instrument and reagent production efficiency and strengthening our ability to meet our responsibility for supplying these products.
・ To enhance the regulatory application process, we will relocate the
Technology Development Division's Clinical Development Department to the Regulatory Affairs & Quality Assurance Division's Regulatory Affairs Department and combine these departments, thereby creating an integrated process spanning clinical trials and clinical studies to regulatory applications.
・ To create clinical value across fields and enhance validation, we will redefine
the roles of the Scientific Affairs Division's Scientific Research Department and Scientific Marketing Department and restructuring these departments.
b) Buttressing the Business Promotion Function to Match the Business Environment
・ To expand our business in the research and industry domains, including entry into the research-oriented flow cytometry market, we will combine the
New Business Development Division and the FCM Business Planning
Department, newly establishing the Research & Industry Business Division.
・ We will newly establish the Biological Material Center within the ICH Business Unit to formulate Group production strategies on biological
materials for diagnostic reagents, as well as to oversee their development, production and the development of production technologies.
・ To augment our product development function related to cervical cancer
screening, we will conduct an expansive reorganization of the Product Development Department, establishing within the UB Product Engineering Division the Product Development 1 Department, which will take charge of urinalysis, and the Product Development 2 Department, which will handle cervical cancer.
・ We will expansively reorganize our Production Department in accordance
with increased production volumes and a growing number of products. In this reorganization, within the Instrument Production Division we will establish the Production 1 Department, to be in charge of i-Square, and the Production 2
Department, taking charge of the Kakogawa Factory.
1 Non-hematology fields: in-vitro diagnostics fields excluding hematology but including immunochemistry, clinical chemistry, hemostasis, urinalysis and
others.
2 Flow cytometry (FCM): Method involving the flow dispersion of minute particles and the use of laser light to optically analyze the minute flows. Used primarily to observe individual cells.
New Organizational Structure
Previous Organizational Structure
2．Personnel Changes and Appointments
(1) Appointments of Senior Executive Officers (Promotions)
Name | New Position | Current Position |
Kaoru Asano | Member of the Managing Board and Senior Executive Officer Managing Director | Member of the Managing Board and Senior Executive Officer |
Kenji Tachibana | Member of the Managing Board and Senior Executive Officer Managing Director | Member of the Managing Board and Senior Executive Officer |
Junzo Yamamoto | Senior Executive Officer | Executive Officer |
(2) Appointments of Executive Officers (Newly Appointed)
Name | New Position |
Juergen Schulze | Executive Officer |
Mamoru Kubota | Executive Officer |
(3) Changes in Operating and Functional Changes of Executive Officers
Name | New Position | Current Position |
Yukio Nakajima | Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Corporate Business Planning Div. Corporate Communication Div. Corporate Business Administration Div. Human Resources & General Affairs Div. Corporate Executive Office Sysmex Business Support Co., Ltd. | Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Corporate Business Planning Div. Corporate Business Administration Div. Human Resources & General Affairs Div. Corporate Executive Office Sysmex Business Support Co., Ltd. |
Koji Tamura | Member of the Managing Board and Senior Executive Officer Managing Director In charge of; LS Business Unit Life Science Product Engineering Div. Sysmex Inostics GmbH | Member of the Managing Board and Senior Executive Officer Managing Director In charge of; LS Business Unit Life Science Product Engineering Div. New Business Development Div. Sysmex Inostics GmbH |
Mitsuru Watanabe | Member of the Managing Board and Senior Executive Officer Managing Director In charge of; HU Business Unit Hematology Product Engineering Div. UB Product Engineering Div. Business Management Dept. | Member of the Managing Board and Senior Executive Officer Managing Director In charge of; HU Business Unit Hematology Product Engineering Div. UB Product Engineering Div. Business Management Dept. FCM Business Planning Dept. Sysmex Partec GmbH |
Name | New Position | Current Position |
Kaoru Asano | Member of the Managing Board and Senior Executive Officer Managing Director In charge of; R&D Strategic Planning Div. Central Research Laboratories Technology Development Div. Medicaroid Corporation Sysmex Engineering Co.,Ltd. RIKEN GENESIS CO., LTD. Vice President of Medicaroid Corporation Director of RIKEN GENESIS CO., LTD. | Member of the Managing Board and Senior Executive Officer In charge of; R&D Strategic Planning Div. Central Research Laboratories Technology Development Div. Medicaroid Corporation Sysmex Engineering Co.,Ltd. RIKEN GENESIS CO., LTD. Executive Vice President of Central Research Laboratories Vice President of Medicaroid Corporation Director of RIKEN GENESIS CO., LTD. |
Kenji Tachibana | Member of the Managing Board and Senior Executive Officer Managing Director In charge of; Business Strategy Development Div. Executive Vice President of Business Strategy Development Div. | Member of the Managing Board and Senior Executive Officer In charge of; Business Strategy Development Div. Executive Vice President of Business Strategy Development Div. |
Michiaki Ishida | Senior Executive Officer In charge of; ICH Business Unit Immunology & Chemistry Product Engineering Div. Hemostasis Product Engineering Div. Business Management Dept. Biological Material Center Sysmex International Reagents Co., Ltd. HYPHEN BioMed, SAS Sysmex Wuxi Co., Ltd. | Senior Executive Officer In charge of; ICH Business Unit Immunology & Chemistry Product Engineering Div. Hemostasis Product Engineering Div. Business Management Dept. Sysmex International Reagents Co., Ltd. HYPHEN BioMed, SAS Sysmex Wuxi Co., Ltd. |
Name | New Position | Current Position |
Takashi Goda | Senior Executive Officer In charge of; Research & Industry Business Div. Solution Development Div. Sysmex Partec GmbH Executive Vice President of Solution Development Div. | Senior Executive Officer In charge of; Business Management (Japan) Div. Sales & Marketing East / Japan Div. Sales & Marketing West / Japan Div. Sysmex TMC Co., Ltd Sysmex CNA Co., Ltd. Sysmex bioMérieux Co., Ltd. |
Junzo Yamamoto | Senior Executive Officer In charge of; Manufacturing Management Div. Instrument Production Div. SCM Div. Sysmex RA Co., Ltd. Sysmex Medica Co., Ltd. Executive Vice President of Instrument Production Div. | Executive Officer In charge of; Instrument Production Div. SCM Div. Sysmex RA Co., Ltd. Sysmex Medica Co., Ltd. Executive Vice President of Instrument Production Div. |
Iwane Matsui | Executive Officer In charge of; Business Management (Japan) Div. Sales & Marketing East / Japan Div. Sales & Marketing West / Japan Div. Sysmex TMC Co., Ltd Sysmex CNA Co., Ltd. Sysmex bioMérieux Co., Ltd. | Executive Officer Executive Vice President of International Business Management Div. Vice President of EMEA & Americas Business Management Dept. |
Keiji Fujimoto | Executive Officer In charge of; Regulatory Affairs & Quality Assurance Div. Scientific Affairs Div. Customer Support Div. | Executive Officer In charge of; Regulatory Affairs & Quality Assurance Div. Scientific Affairs Div. Customer Support Div. Executive Vice President of Regulatory Affairs & Quality Assurance Div. |
Juergen Schulze | Executive Officer President and CEO, Sysmex Europe GmbH | President and CEO, Sysmex Europe GmbH |
Name | New Position | Current Position |
Mamoru Kubota | Executive Officer Executive Vice President of LS Business Unit Life Science Product Engineering Div. | Executive Vice President of LS Business Unit Life Science Product Engineering Div. Vice President of Business Development Dept. |
|
distributed by
|
